@article{3033cb3f4f554cb19e757ae65548577e,
title = "An approach for the transition from systemic immunosuppressants to dupilumab",
author = "\{de Wijs\}, \{L. E.M.\} and Thyssen, \{J. P.\} and C. Vestergaard and Thio, \{H. B.\} and Kunkeler, \{A. C.M.\} and T. Biedermann and Hijnen, \{D. J.\}",
note = "Funding Information: L.E.M. de Wijs, H.B. Thio and A.C.M. Kunkeler have none to declare. J.P. Thyssen attended advisory boards for Eli Lilly, Regeneron, Pfizer, LEO Pharma, AbbVie and Sanofi Genzyme; received speaker honorarium from LEO Pharma, AbbVie, Regeneron and Sanofi Genzyme; and received research grants from Regeneron and Sanofi Genzyme. C. Vestergaard has acted as speaker and/or investigator for Sanofi Genzyme, AbbVie, LEO Pharma, Galapagos, Pierre Fabre Dermo‐Cosmetique and Novartis. D.J. Hijnen has been an investigator for AbbVie, LEO Pharma, Galderma, MedImmune/AstraZeneca, Novartis and Sanofi/Regeneron; and consultant for Regeneron/Sanofi, LEO Pharma, MedImmune/AstraZeneca, Novartis, Incyte, Janssen, Pfizer and Lilly. T. Biedermann has been an institution investigator for AbbVie, LEO Pharma, Novartis, Sanofi/Regeneron, Janssen, Pfizer and Lilly; consultant for Alk‐Abell{\'o}, Mylan, Novartis and Sanofi/Regeneron; and received honorarium for talks or research grant from Alk‐Abell{\'o}, Celgene, Mylan, Novartis, Phadia/Thermo Fisher and Sanofi/Regeneron. ",
year = "2021",
month = mar,
doi = "10.1111/jdv.16941",
language = "English",
volume = "35",
pages = "e221--e223",
journal = "Journal of the European Academy of Dermatology and Venereology",
issn = "0926-9959",
publisher = "John Wiley and Sons Inc.",
number = "3",
}
SDG 3 Good Health and Well-being